Skin cancer on scalp is a serious yet frequently overlooked condition, largely because hair can conceal lesions until they are well advanced.
Understanding the types, warning signs, and available treatments can significantly improve outcomes and, in many cases, lead to a complete cure when the disease is caught early.
Key Takeaways
- The scalp is one of the most sun-exposed areas of the body, making it a common site for basal cell carcinoma, squamous cell carcinoma, and melanoma.
- Early signs of scalp skin cancer include persistent sores, scaly patches, pearly bumps, or moles that change in size, shape, or color.
- Risk factors include prolonged UV exposure, fair skin, a history of sunburns, and thinning or absent hair.
- Treatment options range from surgical excision and Mohs surgery to radiation therapy and targeted systemic therapies for advanced disease.
- Scalp melanoma carries a higher mortality rate than melanoma on other body sites, making early detection and prompt medical care especially critical.
Types of Skin Cancer on Scalp and Who Is Most at Risk
Three main types of skin cancer that appear on the scalp account for the vast majority of diagnosed cases. Basal cell carcinoma (BCC) is the most common overall skin cancer and frequently develops on the scalp, often presenting as a pearly or waxy bump that may ulcerate over time. It grows slowly and rarely spreads, but it can cause significant local tissue destruction if left untreated. Squamous cell carcinoma (SCC) is the second most common type and tends to grow more aggressively than BCC, with a meaningful risk of metastasis, particularly in immunocompromised individuals. Both BCC and SCC are strongly linked to cumulative ultraviolet (UV) radiation exposure over a lifetime.
Scalp melanoma is less common but the most dangerous of the three. Although melanoma accounts for only about 1% of all skin cancer diagnoses globally, it is responsible for the majority of skin cancer deaths, according to the World Health Organization. Scalp melanoma is particularly aggressive — research published in dermatology literature suggests it carries a worse prognosis than melanoma arising on other body locations, possibly because the rich lymphatic network in the scalp facilitates earlier spread.
Scalp skin cancer risk factors are a combination of environmental, biological, and behavioral influences. People with fair skin, light hair, and blue or green eyes are more susceptible because they produce less melanin, the pigment that offers natural UV protection. Individuals who spend significant time outdoors without wearing hats or applying sunscreen are at elevated risk, as are those with a personal or family history of skin cancer. Thinning hair or male-pattern baldness further increases vulnerability by reducing the scalp’s physical barrier against UV rays. Immunosuppression — whether from medication, organ transplantation, or conditions such as HIV — is another important risk factor, as a weakened immune system is less able to recognize and eliminate abnormal cells.
Early Signs and Symptoms of Scalp Skin Cancer
Recognizing skin cancer on scalp symptoms and signs at the earliest possible stage is the single most effective way to improve treatment outcomes. Because the scalp is often hidden beneath hair, many people — and even some clinicians — overlook subtle changes that would be immediately obvious on the face or forearm. Regular self-examination of the scalp, ideally with the help of a mirror or a trusted person, is therefore strongly recommended for anyone in a high-risk group.
The early signs of scalp skin cancer vary depending on the type involved. BCC typically appears as a small, shiny, or pearlescent bump that may have visible blood vessels; over time it can develop a central depression or crust. SCC often starts as a rough, scaly, or thickened patch resembling a persistent sore or wart that does not heal within a few weeks. Both types may bleed easily with minimal trauma, such as combing or brushing the hair.
Melanoma warning signs are best remembered through the established ABCDE criteria:
- Asymmetry: one half of the lesion does not match the other.
- Border: edges are irregular, ragged, notched, or blurred.
- Color: the pigmentation is uneven, with shades of brown, black, red, white, or blue.
- Diameter: the lesion is larger than 6 mm (about the size of a pencil eraser), though melanomas can be smaller.
- Evolving: any change in size, shape, color, or a new symptom such as bleeding or itching.
Additional warning signs include unexplained hair loss around a lesion, persistent scalp tenderness, or a sore that repeatedly heals and then reopens. Any lesion that persists for more than two to four weeks without a clear benign explanation warrants prompt dermatological evaluation.
How to Treat Skin Cancer on the Scalp
Treatment for skin cancer on the scalp depends on the cancer type, its stage, size, and location, as well as the patient’s overall health. Most early-stage, non-melanoma skin cancers are highly curable with local interventions, whereas advanced or metastatic disease requires systemic approaches.
Surgical excision remains the primary treatment for both BCC and SCC, involving removal of the tumor along with a margin of healthy surrounding tissue. For cancers on the scalp — where preserving tissue while achieving clear margins is especially important — Mohs micrographic surgery is often preferred. This technique involves removing the tumor layer by layer while examining each layer under a microscope in real time, enabling the surgeon to confirm complete removal with the smallest possible tissue sacrifice. Cure rates for BCC with Mohs surgery exceed 98% for primary lesions, according to the American College of Mohs Surgery.
When surgery is not feasible due to tumor location, patient health, or the extent of disease, radiation therapy is an effective alternative or adjunct. For advanced or unresectable SCC, targeted therapies such as the anti-PD-1 checkpoint inhibitor cemiplimab are now FDA-approved and have demonstrated significant response rates. Scalp melanoma treatment follows the broader melanoma treatment algorithm: wide local excision with sentinel lymph node biopsy for staging, followed by adjuvant immunotherapy or BRAF/MEK-targeted therapy for high-risk or metastatic disease. Topical treatments such as imiquimod or 5-fluorouracil may be appropriate for superficial lesions or field cancerization but are generally considered second-line options.
| Cancer Type | First-Line Treatment | Advanced/Systemic Options |
|---|---|---|
| Basal Cell Carcinoma | Mohs surgery or surgical excision | Vismodegib, sonidegib (Hedgehog pathway inhibitors) |
| Squamous Cell Carcinoma | Mohs surgery or surgical excision | Cemiplimab (anti-PD-1 immunotherapy) |
| Melanoma | Wide local excision + sentinel node biopsy | Immunotherapy (pembrolizumab, nivolumab), targeted therapy (BRAF/MEK inhibitors) |
Reconstruction of the scalp after surgery can range from primary closure to skin grafting or local flap techniques, depending on the defect size. A multidisciplinary team — including dermatology, surgical oncology, and plastic surgery — typically coordinates care for larger or more complex cases.
Scalp Melanoma: Outlook and When to See a Doctor
Scalp melanoma symptoms and treatment options deserve particular attention because this subtype consistently shows poorer survival statistics compared with melanoma at other anatomical sites. Studies have found that scalp and neck melanomas have a five-year survival rate roughly 10–15 percentage points lower than trunk or extremity melanomas, even when matched for tumor thickness. Experts attribute this in part to delayed diagnosis — the scalp is rarely inspected as carefully as the face — and in part to the dense lymphatic drainage of the scalp, which may facilitate earlier regional spread.
From a treatment standpoint, the principles applied to scalp melanoma are the same as those for melanoma elsewhere, but surgical margins may be more challenging to achieve on the scalp without affecting the pericranium. Adjuvant immunotherapy with checkpoint inhibitors such as pembrolizumab or nivolumab has transformed outcomes for high-risk resected melanoma, reducing recurrence risk by approximately 35–40% in landmark clinical trials. For patients with BRAF V600 mutations — present in approximately 40–50% of cutaneous melanomas — combined BRAF and MEK inhibitor therapy offers an additional systemic option with high initial response rates.
Anyone who notices a new or changing scalp lesion, a sore that does not heal, unexplained hair loss in a localized area, or a mole that meets any of the ABCDE criteria should consult a board-certified dermatologist without delay. Annual full-body skin examinations — including careful inspection of the scalp — are advisable for individuals with any recognized risk factor. When identified early, most skin cancers on the scalp, including melanoma, are treatable and frequently curable.
Frequently Asked Questions
Can you get skin cancer on your scalp even with a full head of hair?
Yes. Hair does not protect the scalp from ultraviolet radiation in the same way sunscreen or a hat does, and UV rays can penetrate through even moderately dense hair. People with thick hair are simply less likely to notice a developing lesion. Regular scalp checks — either personally or during annual dermatology appointments — are important for everyone, regardless of hair density, especially for individuals with other known risk factors.
What is the difference between a benign scalp cyst and a cancerous lesion?
Benign cysts are typically smooth, round, and mobile beneath the skin, and they usually feel the same over time. Cancerous lesions are more likely to be asymmetrical, have irregular borders, change in size or color, bleed without obvious cause, or fail to heal. However, these distinctions are not reliable enough for self-diagnosis. Any new, persistent, or evolving scalp growth should be evaluated by a dermatologist, as only a biopsy can definitively confirm or rule out malignancy.
Is scalp skin cancer more dangerous than skin cancer on other parts of the body?
For melanoma specifically, scalp location is associated with a worse prognosis than many other sites, largely due to delayed diagnosis and the scalp’s rich lymphatic network. For non-melanoma skin cancers such as BCC, the scalp does not inherently carry a higher mortality risk, but SCC on the scalp — particularly in immunocompromised patients — can be locally aggressive. Early detection and treatment remain the most important determinants of outcome across all scalp skin cancer types.
